These three fact sheets were developed by TAG in partnership with the COVID-19 Prevention Network (CoVPN) and the Black AIDS Institute (BAI), and they aim to foster community understanding of COVID-19 vaccine research and development, as well as highlight community perspectives on the topic.
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.
On Wednesday, May 19, 2021,Treatment Action Group (TAG), Black AIDS Institute, (BAI), and the COVID Prevention Trials Network (CoVPN) will convene a virtual news conference and roundtable discussion to disseminate findings from a soon-to-be published report: Breaking Barriers: Surveying Community Perspectives on COVID-19 Vaccine Research.
Today’s decision by the US Food and Drug Administration (FDA) to grant an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA vaccine is an important step toward bringing the COVID-19 pandemic under control in the United States.
AVAC and Treatment Action Group (TAG) welcome today’s announcement that preliminary data from the efficacy trial of Moderna’s mRNA COVID-19 vaccine indicate high-level of protection against COVID-19.
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.
The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.